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Abstract
Background: In two clinical trials, low-grade fever was observed more frequently after coadministration than after
separate administration of two recommended routine pediatric vaccines. Since fever is an important issue with
vaccine tolerability, we performed this open-label study on the efficacy and safety of prophylactic use of
paracetamol (acetaminophen, Benuron®) in children administered routine 7-valent pneumococcal conjugate vaccine
(PCV-7) coadministered with hexavalent vaccine (diphtheria-tetanus-acellular pertussis-hepatitis B, poliovirus,
Haemophilus influenzae type b vaccine [DTPa-HBV-IPV/Hib]) in Germany.
Methods: Healthy infants (N=301) who received a 3-dose infant series of PCV-7 and DTPa-HBV-IPV/Hib plus a
toddler dose were randomly assigned 1:1 to prophylactic paracetamol (125 mg or 250 mg suppositories, based on
body weight) at vaccination, and at 6–8 hour intervals thereafter, or a control group that received no paracetamol.
Rectal temperature and local and other systemic reactions were measured for 4 days post vaccination; adverse
events were collected throughout the study.
Results: In the intent-to-treat population, paracetamol reduced the incidence of fever ≥38°C, but this reduction
was only significant for the infant series, with computed efficacy of 43.0% (95% confidence interval [CI]: 17.4, 61.2),
and not significant after the toddler dose (efficacy 15.9%; 95% CI: −19.9, 41.3); results were similar in the per
protocol (PP) population. Fever >39°C was rare during the infant series, such that there were too few cases for
assessment. After the toddler dose, paracetamol effectively reduced fever >39°C, reaching statistical significance in
the PP population only (efficacy 79%; 95% CI: 3.9, 97.7). Paracetamol also reduced reactogenicity, but there were
few significant differences between groups after any dose. No vaccine-related serious adverse events were reported.
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Conclusions: Paracetamol effectively prevented fever and other reactions, mainly during the infant series. However,
as events were generally mild and of no concern in either group our data support current recommendations to
administer paracetamol to treat symptoms only and not for routine prophylaxis.
Trial registration: NCT00294294
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Background
In two clinical trials, infants who received 7-valent
pneumococcal conjugate vaccine (PCV-7) concomitantly
with a hexavalent vaccine (diphtheria, tetanus, acellular
pertussis, hepatitis B, inactivated poliovirus, Haemophi-
lus influenzae type b [DTPa-HBV-IPV/Hib]) had an al-
most 2-fold higher incidence of febrile reactions than
those who received these combination vaccines alone
[1,2]. Since febrile reactions play a major role in the par-
ents’ perception of vaccine tolerability and might even
stop parents from having their infants immunized, some
health care providers tend to prophylactically administer
paracetamol (acetaminophen, Benuron®) as part of
immunization practice. Data on this preventative strat-
egy are scarce; therefore, to assess this approach, we
performed a study on the effect of prophylactic paraceta-
mol administration on febrile and other common vac-
cine reactions following routine coadministration of
PCV-7 and DTPa-HBV-IPV/Hib.
Methods
Study design and participants
This was an open-label, randomized study conducted at
22 pediatric offices in Germany. The study was approved
by the ethics committee of the Goethe-Universität,
Germany, and conducted from May 2005 to December
2006 in accordance with the Declaration of Helsinki.
Written informed consent was obtained from parents/
legal guardians from all subjects before enrollment.
Healthy infants aged 56–112 days were enrolled in the
study. Contraindications to study participation were a
gestational age <37 weeks and/or a birth weight <2,500 g
and/or a body weight <4,000 g at enrollment; failure to
thrive; immune deficiency or suppression; severe con-
genital malformations or neurological or other severe
chronic disorders; any history of seizures; bleeding disor-
ders; prior administration of blood products, other vac-
cines, or antipyretics for other indications; a known
intolerance to paracetamol or the scheduled vaccines; or
participation in another investigational study.
Interventions
Subjects received PCV-7 (Prevenar®, Pfizer Inc;
containing pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F) and DTPa-HBV-IPV/Hib (INFANRIX hexa™,
GlaxoSmithKline) at ages 2, 3, and 4 months (infant series)
and at age 11–14 months (toddler dose) as 0.5 mL intra-
muscular injections into the left and right anterolateral
thigh, respectively. The prophylaxis group received three
paracetamol suppositories at 6–8h o u ri n t e r v a l s ,
receiving the first immediately after vaccination. Children
weighing <7 kg received paracetamol 375 mg/day; children
weighing 7 to <10 kg received paracetamol 500 mg/day;
and children weighing ≥10 kg received paracetamol
750 mg/day (given as 125mg and 250mg suppositories). If
required for therapeutic purposes, paracetamol was to be
offered to the participants at the investigator’s discretion.
To prevent overdose, subjects in the prophylaxis group
were not to receive paracetamol in addition to their study
medication on the day of vaccination or sooner than 6 hours
after their last dose.
Assessments
In an electronic diary, the parents or legal guardians
recorded the subject’s core (rectal) temperature using a
digital thermometer in the evening of the day of vaccin-
ation (day 1) and in the morning and evening of days
2–4. Fever was defined as the endogenous elevation of
at least one measured body temperature of ≥38°C [3].
Local reactions were measured using a caliper on a
numeric scale from 1 to 14 (or 14+ if larger), and sys-
temic reactions were recorded in the e-diary on days
1–4 along with the time and dose of paracetamol treat-
ment, and any other non-study antipyretic treatment.
Adverse events (AEs) were recorded by the investigator
on the case report form at each visit.
Statistical methods
The sample size was based on the following assump-
tions: the incidence of fever following any of the first
three doses in the control group (without antipyretic
prophylaxis) was 65%; ≥50% reduction in incidence of
fever; ≤15% of subjects would drop out before the end
of the infant series; with alpha =0.05, 2-sided. A total of
120 evaluable subjects per group provided ≥95% power
to show a lower 95% confidence interval (CI) >0 for the
incidence of fever following any of the first three doses.
For the toddler dose, assumptions were as follows: ≥70%
of subjects completing the infant series returned for
their toddler dose; the incidence of fever following the
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tion in incidence of fever was desired; with alpha =0.10,
2-sided. A total of 90 evaluable subjects per group pro-
vided ≥80% power to show a lower 90% CI >0 for the in-
cidence of fever. To ensure an overall sufficient sample
size, 150 subjects per group were to be enrolled.
Participants were randomly assigned in a 1:1 ratio to
the prophylaxis group or to the control group using the
sponsor’s Clinical Operations Randomization Environ-
ment II system with a block size of 4. Subjects who
discontinued after random assignment were not
replaced.
Populations for analysis
The intent-to-treat (ITT) population included any ran-
domly assigned subject, with or without fever ≥38°C who
had at least 1 recorded post vaccination temperature. How-
ever, a decision to include subjects in the actual ITT ana-
lysis of fever (denominator N) was dependent on whether
or not data was missing. To be counted as not having a
fever, all temperature measurements were required. Thus,
if a subject’s highest temperature was 38.5°C and had at
least 1 missing temperature measurement, then this sub-
ject would be included in the analysis of fever ≥38°C and
excluded from the analysis of fever >39°C. Inclusion of
Figure 1 Flow diagram of the trial *Withdrawals from the intent-to-treat (ITT) population are included among withdrawals from the
per protocol (PP) population; subjects may be excluded for more than one reason. MMR=measles, mumps and rubella.
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o t h e r w i s el o w e rt h er a t eo ff e v e rr e p o r t e d .
The per protocol (PP) population included subjects who
received their allocated medication, all four doses of study
vaccine, and had a sufficient number of temperatures
recorded to permit evaluation. For handling missing data
the same logic as for the ITT population was applied. The
safety population included all subjects who received at
least one dose of study vaccine. Subjects who lacked any
safety data (AE, reactogenicity, or temperature) for a par-
ticular vaccination were excluded from that analysis. Sep-
arate safety populations were defined for each vaccination.
The primary endpoint was the incidence of fever (core
temperature ≥38°C) after the infant series and after the
toddler dose in each group. The secondary endpoint was
the incidence of fever >39°C after each dose in each
group. The incidence of fever in the prophylaxis group
relative to the control group (relative risk [RR]) and
2-sided 95% CI estimates of efficacy (1−RR) were
evaluated. The 2-sided, 95% CIs were computed using
exact methods, conditional upon the total number of
subjects reporting fever. If there were fewer than five
subjects with fever in the control group, then only
the estimate of efficacy was computed and no CIs were
presented.
The safety endpoints included the incidence of local and
systemic reactions, and AEs after each vaccination. AEs
were categorized according to the Medical Dictionary for
Regulatory Activities. Comparisons between groups were
performed using a 2-sided Fisher exact test.
Results
A total of 301 subjects were randomly assigned to the
prophylaxis group (n =148) or to the control group (n =
153). Details of the ITT and PP populations are
presented in Figure 1. The demographic characteristics
of the ITT population were generally similar across
groups except that there were slightly more males in the
Table 1 Demographic characteristics: intent-to-treat efficacy population
Prophylaxis group Control group Total
n= 147 n=152 N=299
Gender Female 50.3% 46.7% 48.5%
Male 49.7% 53.3% 51.5%
Race White 98.6% 98% 98.3%
Asian 0.7% 0.7% 0.7%
Black / other 0.7% / 0% 0.7% / 0.7% 0.7% / 0.3%
Body weight* in kg, median (min, max) 5.9 (4.0, 7.6) 5.9 (4.4, 8.2) 5.9 (4.0, 8.2)
Age (months), median (min, max) Dose 1 2.4 (1.9, 3.7) 2.4 (1.9, 3.8) 2.4 (1.9, 3.8)
Dose 2 3.6 (2.8, 5.0) 3.7 (2.7, 5.2) 3.6 (2.7, 5.2)
Dose 3 4.7 (3.8, 6.4) 4.8 (3.8, 6.3) 4.7 (3.8, 6.4)
Toddler dose 11.7 (10.2, 15.8) 11.6 (11.0, 16.8) 11.7 (10.2, 16.8)
* Weight at enrollment.
Table 2 Efficacy of antipyretic prophylaxis in preventing fever within 4 days of vaccination
ITT analysis population PP analysis population
Prophylaxis group Control group Efficacy* Prophylaxis group Control group Efficacy*
% (n/N) % (n/N) % (95% CI) % (n/N) % (n/N) % (95% CI)
Fever ≥38°C Fever ≥38°C
Infant series 43.0 (43/100) 75.4 (95/126) 43.0 (17.4, 61.2) 36.3 (29/80) 75.9 (82/108) 52.3 (26.3, 69.9)
Toddler dose 53.7 (58/108) 63.9 (76/119) 15.9 (−19.9, 41.3) 51.6 (49/95) 61.5 (67/109) 16.1 (−23.1, 43.2)
Fever >39°C Fever >39°C
Dose 1 0 4.0 (5/124) 100.0 (−17.7, 100) 0 4.6 (5/109) 100.0 (−22.6, 100.0)
Dose 2 0 1.8 (2/112) 100.0 (NA) 0 2.0 (2/100) 100.0 (NA)
Dose 3 1.0 (1/102) 1.9 (2/103) 49.5 (NA) 1.1 (1/87) 1.1 (1/91) −4.6 (NA)
Toddler dose 4.6 (4/87) 13.1 (13/99) 65.0 (−13.3, 91.7) 2.6 (2/78) 12.2 (11/90) 79.0 (3.9, 97.7)
*Efficacy is 1− relative risk (prophylaxis group relative to control group). Confidence interval (CI) is computed using exact methods conditional upon the number
of subjects having reported the specific fever. No CI was computed when <5 subjects reported a febrile reaction. Differences between groups is significant if
lower limit of 95% CI >1 for computed efficacy and similar if 95% CI includes 1. ITT intent-to-treat population, PP per-protocol population, N number of subjects
included in the analysis, n number of subjects with the specified degree of fever, NA not applicable.
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of the PP and safety populations were similar to those of
the ITT population (data not shown).
Efficacy of antipyretic prophylaxis
In the ITT analysis population, the incidence of fever
≥38°C during the infant series was significantly reduced
in the prophylaxis group compared with the control
group; however, the toddler dose of paracetamol had no
significant impact on fever ≥38°C (Table 2). Similar re-
sults were observed in the PP analysis population
(Table 2). Fever >39°C after the infant series was an
overall rare event, and was observed in ≤5 subjects, lim-
iting the assessment of paracetamol efficacy in both the
ITT and PP analyses populations. After the toddler dose,
paracetamol’s prevention of fever >39°C reached signifi-
cance in the PP analysis population only (Table 2).
The percentage of subjects administered therapeutic
non-study antipyretics in the ITT population within
15 days post vaccination was higher in the control group
than in the prophylaxis group for both the infant series
(35.5% and 19.6%, respectively) and after the toddler
dose (32.0% and 17.3%, respectively).
Local reactions after PCV-7 and DTPa-HBV-IPV/Hib
The majority of local reactions were mild or moderate in
severity. The incidence of local reactions increased after
the toddler dose. Local reactions were less frequent in
the prophylaxis group; however, statistical significance
was only reached after PCV-7 for tenderness after dose
1 (p= 0.049) and for redness after dose 2 (p =0.017)
(Table 3).
Systemic reactions
Systemic reactions were generally less frequent in the
prophylaxis group with significant differences noted for
fever, rash, irritability, drowsiness, decreased appetite,
persistent inconsolable crying, and decreased activity
after at least one dose in the infant series (all p< 0.05).
After the toddler dose, where systemic reactions oc-
curred more often, only “activity” was significantly de-
creased in the prophylaxis group (p =0.005) (Table 4).
Seventeen serious adverse events (SAEs) were reported
in 10 subjects (three subjects in the control group and
seven in the prophylaxis group), and were medical con-
ditions commonly seen in this age group. Two subjects
in the prophylaxis group experienced seizures; one sub-
ject had an afebrile seizure on day 6 after the third dose
of study vaccine, and one had febrile seizure on day 24
after the toddler dose. No SAEs were considered related
to the study vaccines or study medication. No safety-
related discontinuations or deaths were reported in
this study.
Discussion
This study showed that prophylactic paracetamol signifi-
cantly prevented fever ≥38°C after routine admin-
istration of PCV-7 and DTPa-HBV-IPV/Hib when
Table 3 Local reactions at the PCV-7 and DTPa-HBV-IPV/Hib injection site within 4 days of vaccination – safety population
PCV-7 DTPa-HBV-IPV/Hib
Local reactions Prophylaxis
group
% (n/N)
Control
group
% (n/N)
p-value* Prophylaxis
group
% (n/N)
Control
group
% (n/N)
p-value*
Tenderness
† Dose 1 5.3 (6/114) 12.9 (17/132) 0.049 6.1 (7/114) 11.5 (15/130) 0.180
Dose 2 8.3 (10/120) 14.4 (17/118) 0.157 10.0 (12/120) 15.4 (18/117) 0.244
Dose 3 5.5 (6/109) 10.3 (11/107) 0.216 6.4 (7/109) 10.2 (11/108) 0.337
Toddler dose 21.3 (20/94) 32.7 (35/107) 0.082 21.2 (21/99) 29.9 (32/107) 0.202
Toddler dose/severe 3.4 (3/88) 5.1 (5/98) 0.724 3.4 (3/88) 3.1 (3/98) >0.99
Swelling
‡ Dose 1 9.5 (11/116) 17.2 (23/134) 0.096 17.9 (21/117) 18.2 (24/132) >0.99
Dose 2 17.1 (21/123) 27.2 (34/125) 0.067 23.4 (29/124) 34.6 (44/127) 0.053
Dose 3 16.8 (18/107) 27.7 (31/112) 0.074 21.8 (24/110) 28.1 (32/114) 0.355
Toddler dose 24.2 (23/95) 33.3 (35/105) 0.164 37.3 (38/102) 37.5 (39/104) >0.99
Redness
‡ Dose 1 22.5 (27/120) 27.2 (37/136) 0.470 20.8 (25/120) 23.7 (31/131) 0.650
Dose 1/severe 0.9 (1/114) 0 0.475 0.9 (1/114) 0 0.475
Dose 2 21.1 (26/123) 34.9 (44/126) 0.017 30.4 (38/125) 40.6 (52/128) 0.115
Dose 3 25.4 (29/114) 34.8 (39/112) 0.147 28.9 (33/114) 34.2 (39/114) 0.476
Toddler dose 34.7 (35/101) 44.4 (48/108) 0.160 44.2 (46/104) 48.1 (51/106) 0.583
*Fisher exact test, 2-sided.
† Severe tenderness was defined as present and interfered with limb movement.
‡ Severe swelling and redness was defined as an area >7 cm.
n number of subjects reporting the event, N number of subjects reporting “yes” for at least 1 day or “no” for all days, NA not applicable.
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toddler dose. Fever >39°C was an overall rare event dur-
ing the infant series, limiting a statistical assessment;
however, after the toddler dose, paracetamol significantly
prevented fever >39°C in the PP analysis population, but
not in the ITT analysis population.
Due to the very conservative approach taken of hand-
ling missing data, the incidence of fever reported in this
manuscript may be an over-estimate of the true rate. In-
clusion of subjects with missing data would otherwise
have lowered the rate of fever reported. Therefore, there
is a potential of a bias, which may have caused a reduc-
tion in the assessment of efficacy of prophylactic para-
cetamol. True efficacy may be higher than what is
reported here.
Paracetamol also tended to prevent local reactions at
the injection sites, but for the majority there were no
significant differences between groups, especially after
the toddler dose. Paracetamol significantly reduced the
incidence of all systemic reactions after at least one dose
Table 4 Systemic events within 4 days of PCV-7 and DTPa-HBV-IPV/Hib vaccination –safety population
Systemic event Dose Prophylaxis group % (n/N) Control group % (n/N) p-value*
Fever Dose 1 9.3 (11/118) 35.8 (48/134) <0.001
≥38°C to ≤39°C Dose 2 19.7 (24/122) 43.7 (55/126) 0.000
Dose 3 19.3 (21/109) 45.6 (52/114) 0.000
Toddler dose 51.5 (53/103) 60.0 (69/115) 0.221
>39°C to ≤40°C Dose 1 0 4.0 (5/124) 0.061
Dose 2 0 1.8 (2/112) 0.238
Dose 3 1.0 (1/102) 1.9 (2/103) >0.99
Toddler dose 4.6 (4/87) 13.1 (13/99) 0.072
>40°C
† Toddler dose 0 1.1 (1/95) >0.99
Rash Dose 1 17.6 (21/119) 17.1 (22/129) >0.99
Dose 2 6.8 (8/118) 15.7 (19/121) 0.040
Dose 3 12.7 (14/110) 22.4 (24/107) 0.074
Toddler dose 13.3 (12/90) 23.6 (25/106) 0.098
Irritability Dose 1 47.2 (59/125) 62.1 (87/140) 0.019
Dose 2 42.2 (54/128) 58.5 (76/130) 0.013
Dose 3 39.7 (48/121) 50.0 (59/118) 0.120
Toddler dose 48.2 (53/110) 60.5 (75/124) 0.066
Drowsiness Dose 1 50.4 (65/129) 64.7 (90/139) 0.019
Dose 2 46.5 (59/127) 58.3 (74/127) 0.078
Dose 3 36.4 (43/118) 45.6 (52/114) 0.182
Toddler dose 43.5 (47/108) 50.4 (59/117) 0.350
Decreased appetite Dose 1 30.3 (37/122) 40.0 (54/135) 0.118
Dose 2 26.6 (33/124) 42.7 (53/124) 0.011
Dose 3 23.0 (26/113) 33.6 (37/110) 0.101
Toddler dose 38.2 (39/102) 45.2 (52/115) 0.336
Persistent inconsolable crying Dose 1 9.5 (11/116) 20.0 (26/130) 0.031
Dose 2 9.3 (11/118) 15.8 (19/120) 0.171
Dose 3 14.0 (15/107) 15.3 (17/111) 0.849
Toddler dose 7.8 (7/90) 17.1 (18/105) 0.056
Decreased activity Dose 1 41.6 (52/125) 46.3 (63/136) 0.457
Dose 2 31.0 (39/126) 48.0 (60/125) 0.007
Dose 3 23.3 (27/116) 40.0 (46/115) 0.007
Toddler dose 29.0 (29/100) 48.3 (56/116) 0.005
n = number of subjects experiencing the event. N = Number of subjects reporting “yes” for at least 1 day or “no” for all days.
*Fisher exact test, 2-sided.
†One severe event occurred after toddler dose only.
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cant differences between groups after the toddler dose
except for the assessment of decreased activity, which
was observed less frequently in the paracetamol group.
Our data are generally consistent with that of other
studies [4-7], but not with studies where a single dose of
paracetamol was administered, which reported no sig-
nificant impact on any reactions [8,9]. In all studies,
paracetamol generally seemed to have less impact after
the toddler dose. Two studies in children aged 4–6
years who received a fifth dose of DTPa, or a booster
dose of diphtheria-tetanus-pertussis (whole cell) vaccine,
reported no significant impact of paracetamol on the in-
cidence of local reactions [5,10]. Local reactions in chil-
dren generally occur more frequently after a booster
dose such that the weak anti-inflammatory mechanism
of paracetamol may not be sufficient to control inflam-
mation, suggesting that ibuprofen may be a better alter-
native if required [11].
Of note, recent studies with pneumococcal conjugate
vaccines and DTPa-HBV-IPV/Hib have shown that
prophylactic paracetamol reduced immunogenicity of all
antigens studied. However, a high proportion of partici-
pants still achieved immune responses believed to cor-
relate with protection, suggesting that vaccine efficacy
was not impacted [6,12].
Overall, fever reactions were mainly mild and of little
concern to parents. Fever >39°C was rarely observed
after the infant series and occurred in approximately
13% of the control group after the toddler dose. How-
ever, exposure of a whole population to prophylactic
antipyretics to prevent fever in the minority does not
seem justified, whereas targeted treatment of symptoms
would reduce the number of individuals unnecessarily
exposed to the risk of toxicity [13].
The major limitation of this study was the lack of im-
munogenicity data; this is currently being addressed in a
study assessing the prophylactic use of ibuprofen and
paracetamol on immunogenicity of 13-valent pneumo-
coccal conjugate vaccine when coadministered with
DTPa-HBV-IPV/Hib [14]. The relatively higher dose of
paracetamol used in this study to prevent fever was due
to the lack of availability of suppositories in smaller
doses at the time of the study, limiting weight-adjusted
dosing.
Conclusion
The data support current recommendations [15] that
analgesic/antipyretics should be given only to treat clin-
ically relevant post-vaccination symptoms and not for
routine prophylaxis.
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